These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38384337)

  • 1. Effects of tofersen treatment in patients with
    Wiesenfarth M; Dorst J; Brenner D; Elmas Z; Parlak Ö; Uzelac Z; Kandler K; Mayer K; Weiland U; Herrmann C; Schuster J; Freischmidt A; Müller K; Siebert R; Bachhuber F; Simak T; Günther K; Fröhlich E; Knehr A; Regensburger M; German A; Petri S; Grosskreutz J; Klopstock T; Reilich P; Schöberl F; Hagenacker T; Weyen U; Günther R; Vidovic M; Jentsch M; Haarmeier T; Weydt P; Valkadinov I; Hesebeck-Brinckmann J; Conrad J; Weishaupt JH; Schumann P; Körtvélyessy P; Meyer T; Ruf WP; Witzel S; Senel M; Tumani H; Ludolph AC
    EClinicalMedicine; 2024 Mar; 69():102495. PubMed ID: 38384337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurofilament light-chain response during therapy with antisense oligonucleotide tofersen in SOD1-related ALS: Treatment experience in clinical practice.
    Meyer T; Schumann P; Weydt P; Petri S; Koc Y; Spittel S; Bernsen S; Günther R; Weishaupt JH; Dreger M; Kolzarek F; Kettemann D; Norden J; Boentert M; Vidovic M; Meisel C; Münch C; Maier A; Körtvélyessy P
    Muscle Nerve; 2023 Jun; 67(6):515-521. PubMed ID: 36928619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trial of Antisense Oligonucleotide Tofersen for
    Miller TM; Cudkowicz ME; Genge A; Shaw PJ; Sobue G; Bucelli RC; Chiò A; Van Damme P; Ludolph AC; Glass JD; Andrews JA; Babu S; Benatar M; McDermott CJ; Cochrane T; Chary S; Chew S; Zhu H; Wu F; Nestorov I; Graham D; Sun P; McNeill M; Fanning L; Ferguson TA; Fradette S;
    N Engl J Med; 2022 Sep; 387(12):1099-1110. PubMed ID: 36129998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and patient-reported outcomes and neurofilament response during tofersen treatment in SOD1-related ALS-A multicenter observational study over 18 months.
    Meyer T; Schumann P; Weydt P; Petri S; Weishaupt JH; Weyen U; Koch JC; Günther R; Regensburger M; Boentert M; Wiesenfarth M; Koc Y; Kolzarek F; Kettemann D; Norden J; Bernsen S; Elmas Z; Conrad J; Valkadinov I; Vidovic M; Dorst J; Ludolph AC; Hesebeck-Brinckmann J; Spittel S; Münch C; Maier A; Körtvélyessy P
    Muscle Nerve; 2024 Sep; 70(3):333-345. PubMed ID: 39031772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment of SOD1 ALS with tofersen: a multicentre experience in 17 patients.
    Sabatelli M; Cerri F; Zuccarino R; Patanella AK; Bernardo D; Bisogni G; Tanel R; Sansone V; Filosto M; Lattante S; Martello F; Doronzio PN; Stano S; Zanfini BA; Coccia M; Costantini EM; Lizio A; Lucioli G; Padovani A; Merlini GP; Conte A
    J Neurol; 2024 Aug; 271(8):5177-5186. PubMed ID: 38829431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of neurofilament light and heavy chain in spinal muscular atrophy and amyotrophic lateral sclerosis: A pilot study.
    Li JY; Dai Y; Sun XH; Ren HT; Shen DC; Yang XZ; Liu MS; Cui LY
    Brain Behav; 2023 May; 13(5):e2997. PubMed ID: 37070132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for
    Miller T; Cudkowicz M; Shaw PJ; Andersen PM; Atassi N; Bucelli RC; Genge A; Glass J; Ladha S; Ludolph AL; Maragakis NJ; McDermott CJ; Pestronk A; Ravits J; Salachas F; Trudell R; Van Damme P; Zinman L; Bennett CF; Lane R; Sandrock A; Runz H; Graham D; Houshyar H; McCampbell A; Nestorov I; Chang I; McNeill M; Fanning L; Fradette S; Ferguson TA
    N Engl J Med; 2020 Jul; 383(2):109-119. PubMed ID: 32640130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurofilament markers in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Shi J; Qin X; Chang X; Wang H; Guo J; Zhang W
    J Cell Mol Med; 2022 Jan; 26(2):583-587. PubMed ID: 34866307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characterization of common pathogenic variants of SOD1-ALS in Germany.
    Wiesenfarth M; Forouhideh-Wiesenfarth Y; Elmas Z; Parlak Ö; Weiland U; Herrmann C; Schuster J; Freischmidt A; Müller K; Siebert R; Günther K; Fröhlich E; Knehr A; Simak T; Bachhuber F; Regensburger M; Petri S; Klopstock T; Reilich P; Schöberl F; Schumann P; Körtvélyessy P; Meyer T; Ruf WP; Witzel S; Tumani H; Brenner D; Dorst J; Ludolph AC
    J Neurol; 2024 Aug; ():. PubMed ID: 39141064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profiling tofersen as a treatment of superoxide dismutase 1 amyotrophic lateral sclerosis.
    Oliveira Santos M; de Carvalho M
    Expert Rev Neurother; 2024 Jun; 24(6):549-553. PubMed ID: 38758193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tofersen decreases neurofilament levels supporting the pathogenesis of the SOD1 p.D91A variant in amyotrophic lateral sclerosis patients.
    Weishaupt JH; Körtvélyessy P; Schumann P; Valkadinov I; Weyen U; Hesebeck-Brinckmann J; Weishaupt K; Endres M; Andersen PM; Regensburger M; Dreger M; Koch JC; Conrad J; Meyer T
    Commun Med (Lond); 2024 Jul; 4(1):150. PubMed ID: 39054363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS.
    Benatar M; Zhang L; Wang L; Granit V; Statland J; Barohn R; Swenson A; Ravits J; Jackson C; Burns TM; Trivedi J; Pioro EP; Caress J; Katz J; McCauley JL; Rademakers R; Malaspina A; Ostrow LW; Wuu J;
    Neurology; 2020 Jul; 95(1):e59-e69. PubMed ID: 32385188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression.
    Tortelli R; Ruggieri M; Cortese R; D'Errico E; Capozzo R; Leo A; Mastrapasqua M; Zoccolella S; Leante R; Livrea P; Logroscino G; Simone IL
    Eur J Neurol; 2012 Dec; 19(12):1561-7. PubMed ID: 22680408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [SOD1 gene therapy delays ALS disease progression].
    Forsberg K; Karlsborg M; Salvesen L; Svenstrup K; Winroth I; Berntsson H; M Andersen P
    Lakartidningen; 2024 Apr; 121():. PubMed ID: 38666665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease.
    Poesen K; De Schaepdryver M; Stubendorff B; Gille B; Muckova P; Wendler S; Prell T; Ringer TM; Rhode H; Stevens O; Claeys KG; Couwelier G; D'Hondt A; Lamaire N; Tilkin P; Van Reijen D; Gourmaud S; Fedtke N; Heiling B; Rumpel M; Rödiger A; Gunkel A; Witte OW; Paquet C; Vandenberghe R; Grosskreutz J; Van Damme P
    Neurology; 2017 Jun; 88(24):2302-2309. PubMed ID: 28500227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS.
    Oeckl P; Jardel C; Salachas F; Lamari F; Andersen PM; Bowser R; de Carvalho M; Costa J; van Damme P; Gray E; Grosskreutz J; Hernández-Barral M; Herukka SK; Huss A; Jeromin A; Kirby J; Kuzma-Kozakiewicz M; Amador Mdel M; Mora JS; Morelli C; Muckova P; Petri S; Poesen K; Rhode H; Rikardsson AK; Robberecht W; Rodríguez Mahillo AI; Shaw P; Silani V; Steinacker P; Turner MR; Tüzün E; Yetimler B; Ludolph AC; Otto M
    Amyotroph Lateral Scler Frontotemporal Degener; 2016; 17(5-6):404-13. PubMed ID: 27415180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    De Schaepdryver M; Jeromin A; Gille B; Claeys KG; Herbst V; Brix B; Van Damme P; Poesen K
    J Neurol Neurosurg Psychiatry; 2018 Apr; 89(4):367-373. PubMed ID: 29054919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurofilaments can differentiate ALS subgroups and ALS from common diagnostic mimics.
    Behzadi A; Pujol-Calderón F; Tjust AE; Wuolikainen A; Höglund K; Forsberg K; Portelius E; Blennow K; Zetterberg H; Andersen PM
    Sci Rep; 2021 Nov; 11(1):22128. PubMed ID: 34764380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tofersen: Silver Lining or Hyperbole??
    Chawla T; Goyal V
    Ann Indian Acad Neurol; 2023; 26(5):638-640. PubMed ID: 38022476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis.
    Feneberg E; Oeckl P; Steinacker P; Verde F; Barro C; Van Damme P; Gray E; Grosskreutz J; Jardel C; Kuhle J; Koerner S; Lamari F; Amador MDM; Mayer B; Morelli C; Muckova P; Petri S; Poesen K; Raaphorst J; Salachas F; Silani V; Stubendorff B; Turner MR; Verbeek MM; Weishaupt JH; Weydt P; Ludolph AC; Otto M
    Neurology; 2018 Jan; 90(1):e22-e30. PubMed ID: 29212830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.